Patent Cliff

Key facts

Type

Industry and investor term, not a legal or regulatory status

Underlying event

Loss of exclusivity (LOE) for major products

Key public data

FDA Orange Book and Purple Book patent and exclusivity listings

Well-known example

Generic atorvastatin (Lipitor) entered the U.S. market in late 2011

What is a patent cliff?

The term describes the shape of a revenue chart: sales hold steady or grow while a product is protected, then fall sharply once competitors can launch. A company faces a patent cliff when products responsible for a large share of its revenue lose exclusivity close together.

The phrase is also used at industry level. Around 2011 and 2012, several of the best-selling small-molecule drugs, including atorvastatin (Lipitor) and clopidogrel (Plavix), lost U.S. exclusivity within months of each other. Adalimumab (Humira), long among the best-selling drugs in the world, began facing U.S. biosimilar competition in 2023.

How a patent cliff unfolds

A typical cliff follows a recognizable sequence:

• Protection ends: the last blocking patents and regulatory exclusivities expire, are invalidated or are settled with a licensed entry date.
• Competitors launch: FDA-approved generics or biosimilars enter, sometimes alongside an authorized generic from the brand company.
• Prices and share fall: small-molecule brands usually lose volume quickly once several generics are available, while biosimilar erosion tends to be slower and more uneven.
• The company responds: through new formulations, new indications, acquisitions, licensing deals and cost cuts.

Why patent cliffs matter

For investors and private equity analysts, a looming cliff drives valuations and deal activity, since companies facing large revenue gaps often buy late-stage assets to refill their pipelines. For generic and biosimilar makers, cliffs define the most valuable development targets.

For payers, pharmacy benefit managers and hospital pharmacy buyers, cliffs mark when savings become available and formularies may shift. For competing brands, a rival's cliff can change pricing and contracting across a whole drug class.

Patent cliff vs other revenue pressures

Not every revenue drop is a patent cliff. Medicare drug price negotiation, created by the Inflation Reduction Act of 2022, sets negotiated Medicare prices for selected drugs that have been on the market for years without generic or biosimilar competition, with the first negotiated prices taking effect in 2026. That pressure applies to products that are still protected and is separate from loss of exclusivity, although analysts often model the two together.